| Bioactivity | Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity[1]. |
| Invitro | Futuximab (20 µg/mL; 24-48 h) induces EGFR variant III (EGFRvIII) internalization and slightly reduces EGFRvIII levels in NR6M cells[1]. Western Blot Analysis[1] Cell Line: |
| In Vivo | Futuximab (50 mg/kg; i.p.; twice weekly; for 5 weeks) shows anti-tumor activity in EGFRwt expressing xenograft model[1]. Animal Model: |
| Name | Futuximab |
| CAS | 1310460-85-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stephen T Keir, et al. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498. |